Denali Therapeutics

$62.23
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.12 (-0.19%) Today
$0.00 (0.00%) As of 9:04 PM UTC after-hours

Why Robinhood?

You can buy or sell DNLI and other stocks, options, and ETFs commission-free!

About DNLI

Denali Therapeutics Inc. Common Stock, also called Denali Therapeutics, is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA. The listed name for DNLI is Denali Therapeutics Inc. Common Stock.

CEO
Ryan J. Watts
Employees
261
Headquarters
San Francisco, California
Founded
2013
Market Cap
7.46B
Price-Earnings Ratio
Dividend Yield
Average Volume
1.11M
High Today
$64.17
Low Today
$61.39
Open Price
$63.75
Volume
401.51K
52 Week High
$72.00
52 Week Low
$12.39

Collections

DNLI Earnings

-$0.61
-$0.41
-$0.20
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Feb 25, After Hours

You May Also Like